US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
TW321649B
(it)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5932574A
(en)
*
|
1995-04-27 |
1999-08-03 |
Zeneca Limited |
Quinazoline derivatives
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
JP4471404B2
(ja)
|
1996-02-13 |
2010-06-02 |
アストラゼネカ ユーケイ リミテッド |
Vegfインヒビターとしてのキナゾリン誘導体
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
NZ331191A
(en)
|
1996-03-05 |
2000-03-27 |
Zeneca Ltd |
4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
|
SI0892789T2
(sl)
|
1996-04-12 |
2010-03-31 |
Warner Lambert Co |
Ireverzibilni inhibitorji tirozin kinaz
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
WO1997049688A1
(en)
*
|
1996-06-24 |
1997-12-31 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
EP0837063A1
(en)
*
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
US6002008A
(en)
*
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
DE19743435A1
(de)
|
1997-10-01 |
1999-04-08 |
Merck Patent Gmbh |
Benzamidinderivate
|
JP4652569B2
(ja)
*
|
1998-04-29 |
2011-03-16 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
N−(3−エチニルフェニルアミノ)−6,7−ビス(2−メトキシエトキシ)−4−キナゾリンアミンメシレートの無水物及び一水和物
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
US6384223B1
(en)
|
1998-07-30 |
2002-05-07 |
American Home Products Corporation |
Substituted quinazoline derivatives
|
EP1119349B1
(en)
|
1998-08-18 |
2008-07-02 |
The Regents Of The University Of California |
Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
RS49836B
(sr)
*
|
1999-03-31 |
2008-08-07 |
Pfizer Products Inc., |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
MEP45508A
(en)
|
1999-06-21 |
2011-02-10 |
Boehringer Ingelheim Pharma |
Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
ES2295035T3
(es)
|
1999-07-09 |
2008-04-16 |
Glaxo Group Limited |
Anilinoquinazolinas como inhibidores de proteina tirosina quinasa.
|
GB9922173D0
(en)
*
|
1999-09-21 |
1999-11-17 |
Zeneca Ltd |
Chemical compounds
|
WO2001021594A1
(en)
*
|
1999-09-21 |
2001-03-29 |
Astrazeneca Ab |
Quinazoline compounds and pharmaceutical compositions containing them
|
GB9925958D0
(en)
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
UA72946C2
(uk)
|
1999-11-05 |
2005-05-16 |
Астразенека Аб |
Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
UA74803C2
(uk)
*
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
NZ521421A
(en)
|
2000-04-07 |
2004-09-24 |
Astrazeneca Ab |
Quinazoline compounds
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
EP1170011A1
(en)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Novel use of inhibitors of the epidermal growth factor receptor
|
WO2002016352A1
(en)
|
2000-08-21 |
2002-02-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
ES2282299T3
(es)
|
2000-10-20 |
2007-10-16 |
EISAI R&D MANAGEMENT CO., LTD. |
Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
|
US7776315B2
(en)
|
2000-10-31 |
2010-08-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and additional active ingredients
|
ATE502928T1
(de)
|
2000-11-01 |
2011-04-15 |
Millennium Pharm Inc |
Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
ES2543383T3
(es)
|
2001-02-19 |
2015-08-18 |
Novartis Ag |
Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano
|
JP2002293773A
(ja)
*
|
2001-03-30 |
2002-10-09 |
Sumika Fine Chemicals Co Ltd |
キナゾリン誘導体の製造方法
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
AU2003206068A1
(en)
|
2002-03-01 |
2003-09-16 |
Pfizer Inc. |
Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
|
US7078409B2
(en)
|
2002-03-28 |
2006-07-18 |
Beta Pharma, Inc. |
Fused quinazoline derivatives useful as tyrosine kinase inhibitors
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
DE10221018A1
(de)
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
WO2003097028A1
(en)
|
2002-05-16 |
2003-11-27 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
DK2263691T3
(da)
|
2002-07-15 |
2012-10-22 |
Hoffmann La Roche |
Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4)
|
EP2042517B1
(en)
|
2002-09-27 |
2012-11-14 |
Xencor, Inc. |
Optimized FC variants and methods for their generation
|
US7488823B2
(en)
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
WO2004046101A2
(en)
|
2002-11-20 |
2004-06-03 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
|
JPWO2004060400A1
(ja)
*
|
2003-01-06 |
2006-05-11 |
那波 宏之 |
上皮成長因子受容体を分子標的とする抗精神病薬
|
GB0302882D0
(en)
*
|
2003-02-07 |
2003-03-12 |
Univ Cardiff |
Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
|
US7148231B2
(en)
*
|
2003-02-17 |
2006-12-12 |
Hoffmann-La Roche Inc. |
[6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
PA8595001A1
(es)
|
2003-03-04 |
2004-09-28 |
Pfizer Prod Inc |
Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
|
JPWO2004080462A1
(ja)
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
c−Kitキナーゼ阻害剤
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
AU2004251146A1
(en)
|
2003-05-19 |
2005-01-06 |
Irm, Llc |
Immunosuppressant compounds and compositions
|
AU2004291709C1
(en)
|
2003-05-30 |
2010-03-11 |
Astrazeneca Uk Limited |
Process
|
EP1638600A4
(en)
|
2003-06-09 |
2008-06-11 |
Samuel Waksal |
PROCESS FOR INHIBITING RECEPTOR TYROSINE KINASES WITH AN EXTRACELLULAR ANTAGONIST AND AN INTRA CELLULAR ANTAGONIST
|
KR100753385B1
(ko)
|
2003-06-10 |
2007-08-30 |
에프. 호프만-라 로슈 아게 |
1,3,4-트리아자-페날린 및 1,3,4,6-테트라아자페날린유도체
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
JP2007504122A
(ja)
|
2003-08-29 |
2007-03-01 |
ファイザー・インク |
新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体
|
DK1667991T3
(da)
|
2003-09-16 |
2008-08-18 |
Astrazeneca Ab |
Quinazolinderivater som tyrosinkinaseinhibitorer
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
NZ547633A
(en)
|
2003-11-06 |
2010-08-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
WO2005044788A1
(ja)
|
2003-11-11 |
2005-05-19 |
Eisai Co., Ltd. |
ウレア誘導体およびその製造方法
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2005063739A1
(en)
|
2003-12-23 |
2005-07-14 |
Pfizer Inc. |
Novel quinoline derivatives
|
JP5032851B2
(ja)
|
2004-02-03 |
2012-09-26 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
WO2005080352A2
(en)
|
2004-02-19 |
2005-09-01 |
Rexahn Corporation |
Quinazoline derivatives and therapeutic use thereof
|
ES2387809T3
(es)
|
2004-03-19 |
2012-10-02 |
Imclone Llc |
Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
|
KR101368446B1
(ko)
|
2004-03-31 |
2014-02-28 |
다나-파버 캔서 인스티튜트 인크. |
암에 걸린 인간 환자의 표피성장인자 수용체 표적 치료의 유효 가능성 결정 방법, 키트, 핵산 프로브, 프라이머쌍 및 단리된 단백질
|
RS52545B
(en)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
INHIBITORI PROTEIN APOPTOZE (IAP)
|
WO2005107747A2
(en)
|
2004-05-06 |
2005-11-17 |
Bioresponse, Llc |
Diindolymethane formulations for the treatment of leiomyomas
|
CN102973947A
(zh)
|
2004-06-01 |
2013-03-20 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
CA2579810C
(en)
|
2004-09-17 |
2012-01-24 |
Eisai R&D Management Co., Ltd. |
Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
|
WO2006034488A2
(en)
|
2004-09-23 |
2006-03-30 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
KR101019525B1
(ko)
|
2004-11-12 |
2011-03-07 |
젠코어 인코포레이티드 |
FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
|
WO2006064196A1
(en)
|
2004-12-14 |
2006-06-22 |
Astrazeneca Ab |
Pyrazolopyrimidine compounds as antitumor agents
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
US7989486B2
(en)
|
2004-12-30 |
2011-08-02 |
Bioresponse, L.L.C. |
Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
|
EP1833482A4
(en)
|
2005-01-03 |
2011-02-16 |
Myriad Genetics Inc |
COMPOUNDS AND ITS THERAPEUTIC USE
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
US7625911B2
(en)
|
2005-01-12 |
2009-12-01 |
Mai De Ltd. |
Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
|
TR201901841T4
(tr)
|
2005-01-21 |
2019-03-21 |
Genentech Inc |
Her antikorlarının sabit dozlaması.
|
US20080161251A1
(en)
|
2005-01-21 |
2008-07-03 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
GB0501999D0
(en)
*
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
CN101163684B
(zh)
*
|
2005-02-23 |
2012-08-29 |
盐野义制药株式会社 |
具有酪氨酸激酶抑制作用的喹唑啉衍生物
|
PT1850874E
(pt)
|
2005-02-23 |
2013-12-02 |
Genentech Inc |
Extensão de tempo até a progressão da doença ou sobrevivência em pacientes com cancro de ovário usando pertuzumab
|
AU2006217738A1
(en)
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
RS51821B
(en)
|
2005-02-28 |
2012-02-29 |
Eisai R. &D. Management Co. Ltd. |
NEW COMBINED USE OF SULFONAMIDE UNITS IN CANCER TREATMENT
|
CA2604735A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Nanoparticulate quinazoline derivative formulations
|
CN1854130B
(zh)
*
|
2005-04-15 |
2011-04-20 |
中国医学科学院药物研究所 |
喹唑啉衍生物、及其制法和药物组合物与用途
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
EP2100614B8
(en)
|
2005-06-17 |
2013-11-20 |
ImClone LLC |
Antibody against PDGFR-alpha for use in the treatment of tumours
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
CA2620195A1
(en)
|
2005-08-24 |
2007-03-01 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
EP1928861B1
(en)
|
2005-09-20 |
2010-11-17 |
AstraZeneca AB |
4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
CA2627598C
(en)
|
2005-11-07 |
2013-06-25 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
CA2833852C
(en)
|
2005-11-11 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
NO346575B1
(no)
|
2005-11-21 |
2022-10-17 |
Novartis Ag |
Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin i behandling av carcinoid eller småøyet celle cancer
|
US7960545B2
(en)
|
2005-11-23 |
2011-06-14 |
Natco Pharma Limited |
Process for the prepartion of erlotinib
|
CN101003514A
(zh)
*
|
2006-01-20 |
2007-07-25 |
上海艾力斯医药科技有限公司 |
喹唑啉衍生物、其制备方法及用途
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
EP1984011A4
(en)
|
2006-02-03 |
2010-08-18 |
Imclone Llc |
ANTAGONISTS OF IGF-IR AS ADJUVANTS FOR THE TREATMENT OF PROSTATE CANCER
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
BRPI0709749A2
(pt)
|
2006-04-05 |
2011-07-26 |
Novartis Ag |
combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer
|
JP2009532503A
(ja)
|
2006-04-05 |
2009-09-10 |
ノバルティス アクチエンゲゼルシャフト |
癌を処置するための治療剤の組合せ
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
EP2010521A1
(en)
|
2006-04-19 |
2009-01-07 |
Novartis Ag |
Indazole compounds and methods for inhibition of cdc7
|
RU2469721C2
(ru)
|
2006-05-09 |
2012-12-20 |
Новартис Аг |
Комбинация, включающая комплексон железа и противоопухолевый агент, и ее применение
|
JP5190361B2
(ja)
|
2006-05-18 |
2013-04-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
甲状腺癌に対する抗腫瘍剤
|
WO2007138612A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Vittal Mallya Scientific Research Foundation |
A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4- yl]-(3-ethynylphenyl)amine hydrochloride
|
WO2007138613A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Vittal Mallya Scientific Research Foundation |
A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride
|
CN101547910A
(zh)
|
2006-07-28 |
2009-09-30 |
合成纤维有限公司 |
结晶埃罗替尼
|
EP2383297B8
(en)
|
2006-08-14 |
2023-03-22 |
Xencor, Inc. |
Optimized antibodies that target CD19
|
EP2065372B1
(en)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
WO2008033782A2
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
|
ATE552835T1
(de)
|
2006-09-18 |
2012-04-15 |
Boehringer Ingelheim Int |
Verfahren zur behandlung von tumoren mit egfr- mutationen
|
KR20090073121A
(ko)
|
2006-09-29 |
2009-07-02 |
노파르티스 아게 |
Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘
|
JP2010505811A
(ja)
|
2006-10-04 |
2010-02-25 |
ファイザー・プロダクツ・インク |
カルシウム受容体アンタゴニストとしてのピリド[4,3−d]ピリミジン−4(3H)−オン誘導体
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
US8586621B2
(en)
|
2006-10-27 |
2013-11-19 |
Michael A. Zeligs |
Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
|
US8372856B2
(en)
|
2006-10-27 |
2013-02-12 |
Synthon Bv |
Hydrates of erlotinib hydrochloride
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
WO2008076949A2
(en)
*
|
2006-12-15 |
2008-06-26 |
Concert Pharmaceuticals Inc. |
Quinazoline derivatives and methods of treatment
|
JPWO2008088088A1
(ja)
|
2007-01-19 |
2010-05-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
膵癌治療用組成物
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
US7998949B2
(en)
|
2007-02-06 |
2011-08-16 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
CN101245050A
(zh)
|
2007-02-14 |
2008-08-20 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的盐
|
CA2677651A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
KR20100014512A
(ko)
|
2007-02-21 |
2010-02-10 |
낫코 파마 리미티드 |
엘로티닙 하이드로클로라이드의 신규한 다형체 및 제조방법
|
BRPI0808418A2
(pt)
|
2007-03-02 |
2014-07-22 |
Genentech Inc |
Predição de resposta a um inibidor de her
|
KR20140069232A
(ko)
|
2007-04-04 |
2014-06-09 |
시플라 리미티드 |
에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
|
WO2008150494A1
(en)
|
2007-05-30 |
2008-12-11 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
US20100298156A1
(en)
|
2007-06-08 |
2010-11-25 |
Si Tuen Lee-Hoeflich |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
BRPI0814423B1
(pt)
|
2007-07-17 |
2022-04-19 |
Plexxikon, Inc |
Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
|
WO2009030224A2
(de)
*
|
2007-09-07 |
2009-03-12 |
Schebo Biotech Ag |
Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
|
CA2703767A1
(en)
|
2007-10-29 |
2009-05-07 |
Natco Pharma Limited |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
CL2008003449A1
(es)
|
2007-11-21 |
2010-02-19 |
Imclone Llc |
Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
|
AU2008340053A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as PI 3 kinase inhibitors
|
EP4269443A3
(en)
|
2007-12-26 |
2023-12-27 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
CA2711737C
(en)
*
|
2008-01-18 |
2015-03-31 |
Natco Pharma Limited |
6,7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
JP5336516B2
(ja)
|
2008-02-07 |
2013-11-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
|
PL2268612T3
(pl)
|
2008-03-24 |
2015-02-27 |
Novartis Ag |
Arylosulfonamidowe inhibitory metaloproteinaz macierzy
|
CN101544609A
(zh)
|
2008-03-25 |
2009-09-30 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的结晶形式
|
BRPI0909159A2
(pt)
|
2008-03-26 |
2015-11-24 |
Novartis Ag |
inibidores baseados em hidroxamato de desacetilases b
|
CN102083801A
(zh)
*
|
2008-03-28 |
2011-06-01 |
康瑟特制药公司 |
喹唑啉衍生物和治疗方法
|
EA019183B1
(ru)
|
2008-05-13 |
2014-01-30 |
Астразенека Аб |
Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
|
CA2723984A1
(en)
|
2008-05-14 |
2009-11-19 |
Genomic Health Inc. |
Predictors of patient response to treatment with egf receptor inhibitors
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
DE102008031039A1
(de)
|
2008-06-30 |
2009-12-31 |
Dömling, Alexander, Priv.-Doz. Dr. |
Tarceva zur Anwendung in der Organtransplantation.
|
WO2010015522A1
(de)
|
2008-08-08 |
2010-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US20110223241A1
(en)
|
2008-10-16 |
2011-09-15 |
Celator Pharmaceuticals, Inc. |
Combination methods and compositions
|
CA2742986C
(en)
|
2008-11-07 |
2015-03-31 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
EA018624B1
(ru)
|
2008-11-11 |
2013-09-30 |
Эли Лилли Энд Компани |
Комбинированная терапия ингибитором киназы p70 s6 и ингибитором egfr
|
EP2379498B1
(en)
|
2008-12-18 |
2015-01-21 |
Novartis AG |
Polymorphic form of 1-(4-{1-[(e)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl) -azetidine-3-carboxylic acid
|
KR20110101159A
(ko)
|
2008-12-18 |
2011-09-15 |
노파르티스 아게 |
신규 염
|
RU2518114C3
(ru)
|
2008-12-18 |
2021-11-24 |
Новартис Аг |
Гемифумаратная соль 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил] азетидин-3-карбоновой кислоты
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
ES2396023T3
(es)
|
2009-01-29 |
2013-02-18 |
Novartis Ag |
Bencimidazoles sustituidos para el tratamiento de astrocitomas
|
EP2213281A1
(en)
|
2009-02-02 |
2010-08-04 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20120064072A1
(en)
|
2009-03-18 |
2012-03-15 |
Maryland Franklin |
Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
|
US8440823B2
(en)
*
|
2009-03-26 |
2013-05-14 |
Ranbaxy Laboratories Limited |
Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
|
PT2445903E
(pt)
|
2009-06-26 |
2014-07-08 |
Novartis Ag |
Derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp17
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
LT2451445T
(lt)
|
2009-07-06 |
2019-06-25 |
Boehringer Ingelheim International Gmbh |
Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas
|
US9050341B2
(en)
*
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
AU2010283806A1
(en)
|
2009-08-12 |
2012-03-01 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
MX2012002179A
(es)
|
2009-08-20 |
2012-03-16 |
Novartis Ag |
Compuestos heterociclicos de oxima.
|
WO2011023677A1
(en)
|
2009-08-26 |
2011-03-03 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US20120220594A1
(en)
|
2009-10-30 |
2012-08-30 |
Bristol-Meyers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
AU2010317167B2
(en)
|
2009-11-04 |
2012-11-29 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful as MEK inhibitors
|
JP2013510564A
(ja)
|
2009-11-13 |
2013-03-28 |
パンガエア ビオテック、ソシエダッド、リミターダ |
肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
|
JP6184695B2
(ja)
|
2009-12-04 |
2017-08-23 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体、抗体アナログ、組成物、及び方法
|
WO2011070030A1
(en)
|
2009-12-08 |
2011-06-16 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
EP2348020A1
(en)
|
2009-12-23 |
2011-07-27 |
Esteve Química, S.A. |
Preparation process of erlotinib
|
WO2011086053A1
(en)
|
2010-01-12 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
WO2011107664A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
WO2011113802A2
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
CA2794745A1
(en)
|
2010-03-29 |
2011-10-06 |
Zymeworks, Inc. |
Antibodies with enhanced or suppressed effector function
|
EP2558864A1
(en)
|
2010-04-16 |
2013-02-20 |
Genentech, Inc. |
Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
DE202010006543U1
(de)
|
2010-05-07 |
2010-09-09 |
Ratiopharm Gmbh |
Erlotinibresinat
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP2592083A4
(en)
|
2010-05-21 |
2014-01-22 |
Shenzhen Salubris Pharm Co Ltd |
CONDENSED QUINAZOLINE DERIVATIVES AND USES THEREOF
|
WO2011147102A1
(zh)
*
|
2010-05-28 |
2011-12-01 |
翔真生物科技股份有限公司 |
6,7-取代基-4-苯胺类喹唑啉的合成方法
|
KR101677790B1
(ko)
|
2010-06-25 |
2016-11-18 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
NZ606042A
(en)
*
|
2010-07-23 |
2015-05-29 |
Generics Uk Ltd |
Process for the preparation of erlotinib and salts thereof
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
MX2013003019A
(es)
|
2010-09-15 |
2013-05-28 |
Hoffmann La Roche |
Compuestos de azabenzotiazol, composiciones y metodos de uso.
|
JP2013537210A
(ja)
|
2010-09-16 |
2013-09-30 |
ノバルティス アーゲー |
17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
|
IT1402029B1
(it)
|
2010-10-14 |
2013-08-28 |
Italiana Sint Spa |
Procedimento per la preparazione di erlotinib
|
WO2012065161A2
(en)
|
2010-11-12 |
2012-05-18 |
Scott & White Healthcare |
Antibodies to tumor endothelial marker 8
|
CN103313987A
(zh)
|
2010-11-19 |
2013-09-18 |
弗·哈夫曼-拉罗切有限公司 |
吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途
|
EP2643314B1
(en)
*
|
2010-11-25 |
2016-07-13 |
ratiopharm GmbH |
Novel salts and polymorphic forms of afatinib
|
DE102010053124A1
(de)
|
2010-12-01 |
2012-06-06 |
Volkswagen Ag |
Kupplung, insbesondere für ein Getriebe eines Kraftfahrzeuges, vorzugsweise Doppelkupplung für ein automatisches oder automatisiertes Doppelkupplungsgetriebe
|
CN103270026A
(zh)
|
2010-12-21 |
2013-08-28 |
诺瓦提斯公司 |
作为vps34抑制剂的联-杂芳基化合物
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
WO2012104776A1
(en)
|
2011-01-31 |
2012-08-09 |
Novartis Ag |
Novel heterocyclic derivatives
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
AU2012225693A1
(en)
|
2011-03-04 |
2013-09-19 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
WO2012122513A2
(en)
|
2011-03-10 |
2012-09-13 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
AU2012246490B2
(en)
|
2011-04-18 |
2016-08-04 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
CN103649073B
(zh)
|
2011-04-28 |
2016-04-13 |
诺瓦提斯公司 |
17α-羟化酶/C17,20-裂合酶抑制剂
|
CN102918029B
(zh)
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
EA201391820A1
(ru)
|
2011-06-09 |
2014-12-30 |
Новартис Аг |
Гетероциклические сульфонамидные производные
|
EP2721007B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl isoquinolinone compounds
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
CN102267952B
(zh)
*
|
2011-06-21 |
2013-12-11 |
天津市汉康医药生物技术有限公司 |
喹唑啉类化合物、其制备方法和用途
|
MX2013015001A
(es)
|
2011-06-27 |
2014-03-31 |
Novartis Ag |
Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
|
US8575339B2
(en)
*
|
2011-07-05 |
2013-11-05 |
Xueheng Cheng |
Derivatives of erlotinib
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
EP2742040B1
(en)
|
2011-08-12 |
2016-04-06 |
F.Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
EP2742067A4
(en)
|
2011-08-12 |
2015-03-04 |
Omeros Corp |
MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
|
KR20140057356A
(ko)
|
2011-08-31 |
2014-05-12 |
제넨테크, 인크. |
진단 마커
|
UY34329A
(es)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
Compuestos de triazolopiridina
|
CN103827115A
(zh)
|
2011-09-20 |
2014-05-28 |
弗·哈夫曼-拉罗切有限公司 |
咪唑并吡啶化合物、组合物和使用方法
|
AU2012321248A1
(en)
|
2011-09-30 |
2014-04-24 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to EGFR kinase inhibitor in tumours or tumour cells
|
HU230483B1
(hu)
|
2011-10-10 |
2016-07-28 |
Egis Gyógyszergyár Nyrt. |
Erlotinib sók
|
US20140309229A1
(en)
|
2011-10-13 |
2014-10-16 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
SG11201401716XA
(en)
|
2011-10-28 |
2014-05-29 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
JP5992054B2
(ja)
|
2011-11-29 |
2016-09-14 |
ノバルティス アーゲー |
ピラゾロピロリジン化合物
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
PT2794600T
(pt)
|
2011-12-22 |
2018-03-13 |
Novartis Ag |
Derivados de 2,3-di-hidro-benzo[1,4]oxazina e compostos relacionados como inibidores de fosfoinositídeo-3-cinase (pi3k) para o tratamento de, por exemplo, artrite reumatoide
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
JP2015503515A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Bcl2と結合相手の相互作用を阻害するための化合物および組成物
|
EA201491259A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
|
US20140357633A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
MX2014007730A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
AU2012355619A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
KR101721678B1
(ko)
|
2012-03-08 |
2017-03-31 |
할로자임, 아이엔씨 |
조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
|
CA2865082A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
WO2013149581A1
(en)
|
2012-04-03 |
2013-10-10 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
NZ700924A
(en)
|
2012-05-16 |
2016-02-26 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
US9365576B2
(en)
|
2012-05-24 |
2016-06-14 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
US9789193B2
(en)
|
2012-06-15 |
2017-10-17 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
US9593083B2
(en)
|
2012-09-04 |
2017-03-14 |
Shilpa Medicare Limited |
Crystalline erlotinib hydrochloride process
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
EP2948453B1
(en)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
WO2014118112A1
(en)
|
2013-01-29 |
2014-08-07 |
Synthon B.V. |
Pharmaceutical composition comprising erlotinib hydrochloride
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
US9834575B2
(en)
|
2013-02-26 |
2017-12-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
EP2970307B1
(en)
|
2013-03-13 |
2020-03-11 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
JP2016512835A
(ja)
|
2013-03-15 |
2016-05-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤の組み合わせ及びそれらの使用
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
SG11201509278XA
(en)
|
2013-05-14 |
2015-12-30 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
MX2016002794A
(es)
|
2013-09-05 |
2016-09-13 |
Genentech Inc |
Compuestos antiproliferativos.
|
WO2015035410A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutic, Inc. |
Cancer therapy
|
KR20160055253A
(ko)
|
2013-09-12 |
2016-05-17 |
할로자임, 아이엔씨 |
변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
|
BR112016003229A8
(pt)
|
2013-09-22 |
2020-02-04 |
Calitor Sciences Llc |
composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
|
AR097894A1
(es)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
JP2016539149A
(ja)
|
2013-12-06 |
2016-12-15 |
ノバルティス アーゲー |
アルファ−アイソフォーム選択的ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン
|
JP2017501167A
(ja)
|
2013-12-17 |
2017-01-12 |
ジェネンテック, インコーポレイテッド |
Ox40結合アゴニスト及びpd−1軸結合アンタゴニストを含む併用療法
|
PT3083686T
(pt)
|
2013-12-17 |
2019-12-18 |
Hoffmann La Roche |
Métodos de tratamento de cancros com antagonistas da ligação ao eixo pd-1 e taxanos
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
EP3122728A4
(en)
|
2014-03-28 |
2017-10-25 |
Calitor Sciences, LLC |
Substituted heteroaryl compounds and methods of use
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
MA51552A
(fr)
|
2014-03-31 |
2021-03-24 |
Hoffmann La Roche |
Anticorps anti-ox40 et procédés d'utilisation
|
AU2015241198A1
(en)
|
2014-04-03 |
2016-11-17 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
CN107207510B
(zh)
|
2014-07-31 |
2019-11-29 |
诺华股份有限公司 |
联合疗法
|
JO3783B1
(ar)
|
2014-08-28 |
2021-01-31 |
Eisai R&D Man Co Ltd |
مشتق كوينولين عالي النقاء وطريقة لإنتاجه
|
EP3189046B1
(en)
|
2014-09-05 |
2020-08-26 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
EP3193866A1
(en)
|
2014-09-19 |
2017-07-26 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
WO2016059600A1
(en)
|
2014-10-17 |
2016-04-21 |
Novartis Ag |
Combination of ceritinib with an egfr inhibitor
|
CA2908441A1
(en)
|
2014-10-28 |
2016-04-28 |
Cerbios-Pharma Sa |
Process for the preparation of erlotinib
|
KR20170086540A
(ko)
|
2014-11-03 |
2017-07-26 |
제넨테크, 인크. |
T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
|
SG11201703521UA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
EP3218376B1
(en)
|
2014-11-10 |
2019-12-25 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
US20160166685A1
(en)
|
2014-11-17 |
2016-06-16 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US9763922B2
(en)
|
2014-11-27 |
2017-09-19 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
WO2016082879A1
(en)
*
|
2014-11-27 |
2016-06-02 |
Synthon B.V. |
Pharmaceutical composition comprising erlotinib hydrochloride
|
MX2017006864A
(es)
|
2014-12-23 |
2017-08-28 |
Genentech Inc |
Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia.
|
WO2016105503A1
(en)
|
2014-12-24 |
2016-06-30 |
Genentech, Inc. |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
CN107406418B
(zh)
|
2015-01-09 |
2021-10-29 |
基因泰克公司 |
4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途
|
CN107406414B
(zh)
|
2015-01-09 |
2022-04-19 |
基因泰克公司 |
作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物
|
CN107406429B
(zh)
|
2015-01-09 |
2021-07-06 |
基因泰克公司 |
哒嗪酮衍生物及其在治疗癌症中的用途
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
HUE064614T2
(hu)
|
2015-02-25 |
2024-04-28 |
Eisai R&D Man Co Ltd |
Eljárás egy kinolin-származék keserû ízének elnyomására
|
CN104725327B
(zh)
*
|
2015-03-03 |
2017-08-25 |
山东大学 |
一种盐酸厄洛替尼的环保制备方法
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
HRP20201900T4
(hr)
|
2015-05-12 |
2024-06-07 |
F. Hoffmann - La Roche Ag |
Terapeutski i dijagnostički postupci kod raka
|
WO2016196298A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Therapeutic and diagnolstic methods for cancer
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
CN107750164A
(zh)
|
2015-06-08 |
2018-03-02 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体和pd‑1轴结合拮抗剂治疗癌症的方法
|
EP3311841B1
(en)
|
2015-06-16 |
2021-07-28 |
PRISM BioLab Co., Ltd. |
Anticancer agent
|
AU2016280070B2
(en)
|
2015-06-17 |
2022-09-15 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
|
CN105017162B
(zh)
*
|
2015-06-26 |
2017-10-27 |
陕西师范大学 |
4‑对丙烯基苯氨基喹唑啉衍生物及其在制备抗肿瘤药物中的应用
|
DK3341376T3
(da)
|
2015-08-26 |
2021-03-29 |
Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio |
Kondenserede tricykliske forbindelser som proteinkinase-inhibitorer
|
ES2761885T3
(es)
|
2015-08-28 |
2020-05-21 |
Novartis Ag |
Combinaciones farmacéuticas que comprenden (a) el inhibidor de la cinasa dependiente de ciclina 4/6 (CDK4/6) LEE011 (= ribociclib) y (b) el inhibidor del receptor del factor de crecimiento epidérmico (EGFR) erlotinib, para el tratamiento o la prevención del cáncer
|
AR105910A1
(es)
|
2015-09-04 |
2017-11-22 |
Obi Pharma Inc |
Matrices de glicano y método de uso
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
MY186016A
(en)
|
2015-09-25 |
2021-06-14 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
CA3002954A1
(en)
|
2015-11-02 |
2017-05-11 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
US10906918B2
(en)
|
2015-12-16 |
2021-02-02 |
Genentech, Inc. |
Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
CN114395624A
(zh)
|
2016-02-29 |
2022-04-26 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3436482A4
(en)
|
2016-03-29 |
2020-03-11 |
OBI Pharma, Inc. |
ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
AU2017249229A1
(en)
|
2016-04-15 |
2018-10-04 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
CA3020718A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
BR112018071683A2
(pt)
|
2016-04-22 |
2019-02-19 |
Obi Pharma, Inc. |
método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
EP3464286B1
(en)
|
2016-05-24 |
2021-08-18 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
CN109476641B
(zh)
|
2016-05-24 |
2022-07-05 |
基因泰克公司 |
Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
|
EP4371570A2
(en)
|
2016-06-08 |
2024-05-22 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
JP2019527037A
(ja)
|
2016-06-08 |
2019-09-26 |
ジェネンテック, インコーポレイテッド |
がんのための診断及び治療方法
|
KR20190067765A
(ko)
|
2016-07-27 |
2019-06-17 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
US11643456B2
(en)
|
2016-07-29 |
2023-05-09 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック, インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
MX2019003934A
(es)
|
2016-10-06 |
2019-07-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
CA3044274A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
UA124474C2
(uk)
|
2016-12-22 |
2021-09-22 |
Емджен Інк. |
БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
|
WO2018160841A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CN106928069B
(zh)
*
|
2017-03-21 |
2019-03-19 |
上海玉函化工有限公司 |
一种4,5-二(2-甲氧基乙氧基)-2-硝基苯甲酸乙酯的制备方法
|
JP2020516638A
(ja)
|
2017-04-13 |
2020-06-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを処置する方法における使用のための、インターロイキン2イムノコンジュゲート、cd40アゴニスト、および任意選択のpd−1軸結合アンタゴニスト
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
CN107200715B
(zh)
*
|
2017-06-22 |
2020-05-29 |
陕西师范大学 |
喹唑啉衍生物及其在制备抗肿瘤药物中的应用
|
EP3655034A1
(en)
|
2017-07-21 |
2020-05-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP2020530297A
(ja)
|
2017-08-11 |
2020-10-22 |
ジェネンテック, インコーポレイテッド |
抗cd8抗体及びその使用
|
KR20200041387A
(ko)
|
2017-09-08 |
2020-04-21 |
에프. 호프만-라 로슈 아게 |
암의 진단 및 치료 방법
|
AU2018329920B2
(en)
|
2017-09-08 |
2022-12-01 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
KR20200078495A
(ko)
*
|
2017-09-26 |
2020-07-01 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
암 치료를 위한 조성물 및 방법
|
US11369608B2
(en)
|
2017-10-27 |
2022-06-28 |
University Of Virginia Patent Foundation |
Compounds and methods for regulating, limiting, or inhibiting AVIL expression
|
AU2018359967A1
(en)
|
2017-11-06 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3740468A4
(en)
|
2018-01-20 |
2021-10-06 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHOD OF USING
|
JP7307733B2
(ja)
|
2018-01-26 |
2023-07-12 |
エグゼリクシス, インコーポレイテッド |
キナーゼ依存的障害を処置するための化合物
|
MA51679A
(fr)
|
2018-01-26 |
2020-12-02 |
Exelixis Inc |
Composés destinés au traitement de troubles dépendant de la kinase
|
MA51673A
(fr)
|
2018-01-26 |
2020-12-02 |
Exelixis Inc |
Composés destinés au traitement de troubles dépendant de la kinase
|
TWI660728B
(zh)
*
|
2018-02-09 |
2019-06-01 |
國立交通大學 |
胺基喹唑啉衍生物及其醫藥組合物與用途
|
KR20200135313A
(ko)
|
2018-02-26 |
2020-12-02 |
제넨테크, 인크. |
항-tigit 및 항-pd-l1 길항제 항체에 의한 치료를 위한 투약
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
AU2019265822A1
(en)
|
2018-05-10 |
2020-11-19 |
Amgen Inc. |
KRAS G12C inhibitors for the treatment of cancer
|
EP3797173A2
(en)
|
2018-05-21 |
2021-03-31 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
EP3802535B1
(en)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Kras g12c inhibitors and methods of using the same
|
EP4268898A3
(en)
|
2018-06-11 |
2024-01-17 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
WO2019246557A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
CN110642796B
(zh)
*
|
2018-06-27 |
2023-03-17 |
烟台药物研究所 |
一种喹唑啉类衍生物及其应用
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
JP2021530502A
(ja)
|
2018-07-18 |
2021-11-11 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
MX2021003214A
(es)
|
2018-09-19 |
2021-05-12 |
Genentech Inc |
Metodos terapeuticos y de diagnostico para el cancer de vejiga.
|
AU2019342133A1
(en)
|
2018-09-21 |
2021-04-22 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
EP3856726A1
(en)
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
AU2019352741A1
(en)
|
2018-10-04 |
2021-05-06 |
Assistance Publique-Hôpitaux De Paris (Aphp) |
EGFR inhibitors for treating keratodermas
|
WO2020081767A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
EP3883565A1
(en)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JOP20210154B1
(ar)
|
2018-12-20 |
2023-09-17 |
Amgen Inc |
مثبطات kif18a
|
MX2021007104A
(es)
|
2018-12-20 |
2021-08-11 |
Amgen Inc |
Inhibidores de kif18a.
|
US20220056015A1
(en)
|
2018-12-20 |
2022-02-24 |
Amgen Inc. |
Kif18a inhibitors
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
BR112021011894A2
(pt)
|
2018-12-21 |
2021-09-08 |
Daiichi Sankyo Company, Limited |
Composição farmacêutica
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2020172712A1
(en)
|
2019-02-27 |
2020-09-03 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
CN113767100A
(zh)
|
2019-03-01 |
2021-12-07 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
AU2020232616A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
MX2021013222A
(es)
|
2019-05-03 |
2022-01-06 |
Genentech Inc |
Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
KR20220011670A
(ko)
|
2019-05-21 |
2022-01-28 |
암젠 인크 |
고체 상태 형태
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
AU2020324406A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
JP2022542967A
(ja)
|
2019-08-02 |
2022-10-07 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
CA3152528A1
(en)
|
2019-09-04 |
2021-03-11 |
Genentech, Inc. |
Cd8 binding agents and uses thereof
|
TW202126651A
(zh)
|
2019-09-26 |
2021-07-16 |
美商艾克塞里克斯公司 |
吡啶酮化合物及使用方法
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
CA3155857A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
BR112022008535A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
|
TW202132315A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras 抑制劑
|
US20220389103A1
(en)
|
2019-11-06 |
2022-12-08 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
WO2021092115A1
(en)
|
2019-11-08 |
2021-05-14 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
US20210161897A1
(en)
|
2019-11-12 |
2021-06-03 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
CR20220207A
(es)
|
2019-11-13 |
2022-06-06 |
Genentech Inc |
Compuestos terapéuticos y métodos de uso
|
MX2022005726A
(es)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
US20230192681A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
US11845799B2
(en)
|
2019-12-13 |
2023-12-19 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
KR20220124768A
(ko)
|
2020-01-07 |
2022-09-14 |
레볼루션 메디슨즈, 인크. |
Shp2 억제제 투여 및 암 치료방법
|
US20230056604A1
(en)
|
2020-01-20 |
2023-02-23 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
JP2023511595A
(ja)
|
2020-01-27 |
2023-03-20 |
ジェネンテック, インコーポレイテッド |
抗tigitアンタゴニスト抗体を用いたがんを処置するための方法
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
JP2023531406A
(ja)
|
2020-06-16 |
2023-07-24 |
ジェネンテック, インコーポレイテッド |
トリプルネガティブ乳がんを処置するための方法および組成物
|
KR20230024368A
(ko)
|
2020-06-18 |
2023-02-20 |
제넨테크, 인크. |
항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
|
JP2023530351A
(ja)
|
2020-06-18 |
2023-07-14 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Ras阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法
|
EP4172621A1
(en)
|
2020-06-30 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
|
CN115843335A
(zh)
|
2020-06-30 |
2023-03-24 |
国家医疗保健研究所 |
用于预测患有实体癌的患者在术前辅助治疗和根治性手术后复发和/或死亡风险的方法
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
JP2023541816A
(ja)
|
2020-08-27 |
2023-10-04 |
イノージ・セラピューティクス・コーポレイション |
自己免疫性疾患および癌を治療するための方法および組成物
|
WO2022060583A1
(en)
|
2020-09-03 |
2022-03-24 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
CN117683049A
(zh)
|
2020-09-15 |
2024-03-12 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
CA3196277A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
EP4267250A1
(en)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
EP4291558A1
(en)
|
2021-02-12 |
2023-12-20 |
F. Hoffmann-La Roche AG |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
CA3211063A1
(en)
|
2021-02-19 |
2022-08-25 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
AU2022270116A1
(en)
|
2021-05-05 |
2023-12-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
AU2022268962A1
(en)
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
EP4347603A1
(en)
|
2021-05-25 |
2024-04-10 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
AU2022315530A1
(en)
|
2021-07-20 |
2024-01-18 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their preparation, and uses
|
EP4384522A1
(en)
|
2021-08-10 |
2024-06-19 |
Erasca, Inc. |
Selective kras inhibitors
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023187037A1
(en)
|
2022-03-31 |
2023-10-05 |
Astrazeneca Ab |
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024002938A1
(en)
|
2022-06-27 |
2024-01-04 |
Astrazeneca Ab |
Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024088808A1
(en)
|
2022-10-24 |
2024-05-02 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|